Best Value summary: 2019/20 – quarter 4

The following table provides an update on availability of best value products and when they should be considered within the MO CQUIN. This is a "live" document which is based on information available at the time of writing; the list will be updated and circulated as new information becomes available.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Drug name** | **Description** | **On CMU framework from** | **Indications not included** | **Comments** |
| Bosentan | Generics | 01/08/2018 |  | Full year effects from 2018/19 |
| Tenofovir disoproxil | Generics | 01/08/2018 |  | Full year effects from 2018/19 |
| Glatiramer acetate | Generics | 01/08/2018 |  | Full year effects from 2018/19 |
| Mycophenolic acid | Generics | 01/08/2018 |  | Full year effects from 2018/19 |
| Anidulafungin | Generics | 01/08/2018 |  | Full year effects from 2018/19 |
| Tadalafil | Generics | 01/08/2018 |  | Full year effects from 2018/19 |
| Nitisinone | Generics | 01/08/2018 |  | Full year effects from 2018/19 |
| Trastuzumab (FYE) | Biosimilar | 16/07/2018 |  | Full year effects from 2018/19 |
| Adalimumab (FYE) | Biosimilar | 01/12/2018 |  | Full year effects from 2018/19. Reference price from 1st April 2019 so not within BV savings |
| Tenofovir disoproxil/emtricitabine/efavirenz | Generics (Atripla) | 01/05/19 |  | Phased implementation |
| Tenofovir DF/emtricitabine | Generics (Truvada) | 01/05/19 |  | Phased implementation |
| Atazanavir (capsule) | Generics | 01/10/19 |  |  |
| Atovaquone (oral suspension) | Generics | 01/10/19 |  |  |
| Bortezomib (solution/powder for solution for injection) | Generics | 01/10/19 |  |  |
|  |  |  |  |  |  |
| Clofarabine (solution for injection) | Generics | 01/10/19 |  |  |
| Darunavir (tablet) | Generics | 01/10/19 |  |  |
| Ganciclovir (powder for solution for infusion) | Generics | 01/10/19 |  |  |
| Gefitinib (tablet) | Generics | 01/10/19 |  | Agree use locally. |
| Miglustat (capsule) | Generic | 01/10/19 |  |  |
| Ritonavir (tablet) | Generic | 01/10/19 |  |  |
| Azacitidine | Generic | 01/02/2020 |  | Planned for T2 transition |
| Deferiprone | Generic | 01/02/2020 |  | Planned for T2 transition |
| Lopinavir/ritonavir | Generic | 01/02/2020 |  | Planned for T2 transition |
| Posaconazole | Generics | 01/02/2020 |  | Planned for T2 transition |
| Sodium oxybate | Generics | 01/02/2020 |  | Planned for T2 transition |
| Vinorelbine | Generics | 01/02/2020 |  | Planned for T2 transition |